Roche completed the acquisition of Flatiron Health for $1.9bn.

Roche, a pioneer in pharmaceuticals and diagnostics completed the acquisition of Flatiron Health, a healthcare technology, and services company for $1.9bn. Flatiron Health will continue its operations as a separate legal entity and its current business model, a network of partnerships and overall objectives remain. The integrity of segregated patient protected health information will be preserved, as will dedicated sales and marketing, provider-facing and life science business activities "This important milestone will allow us to increase our investments in our provider-facing technology and services platform, as well as our evidence-generation platform, which will remain available to the entire healthcare industry.” Nat Turner, Flatiron Co-Founder and CEO.